SBIR-STTR Award

Neuroprotective Therapy of Stroke with Hucnc and Simvastatin
Profile last edited on: 4/3/2019

Program
STTR
Agency
NIH | NINDS
Total Award Amount
$176,926
Award Phase
1
Principal Investigator
Jieli Chen
Activity Indicator

Company Information

Saneron CCEL Therapeutics Inc (AKA:CCel Bio-Therapies Inc)

13014 North Dale Mabry Highwat Suite 266
Tampa, FL 33618
   (813) 977-7664
   nkn@saneron-ccel.com
   www.saneron-ccel.com
Multiple Locations:   
Congressional District:   14
County:   Hillsborough

Phase I

Phase I year
2010
Phase I Amount
$176,926
There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow stem cells and therefore potentially more vigorous. Our preliminary data show that the combination of sub-therapeutic doses of simvastatin with HUCBCs increases exogenously administered cell migration into the ischemic brain, and additively improves the cell-based therapeutic outcome after stroke. Thus, altering the ischemic tissue with agents to promote a cell receptive microenvironment may amplify the therapeutic modality of cell-based therapy. We propose that cell-based therapy can be enhanced by making the tissue more receptive to the administered cells by creating a microenvironment within the ischemic cerebral tissue that facilitates cell-based induction of brain plasticity. In this proposal, we seek to investigate the effect of combination of simvastatin and HUCBCs to amplify the therapeutic effect of HUCBC cell-based therapy, to improve the functional outcome after stroke. We will test the effects of combination cell-based and pharmacological therapies in a clinically relevant model of embolic stroke in rat. In Aim 1, we hypothesize that the combination treatment of stroke with HUCBCs and simvastatin promotes additive or super-additive improvement of neurological functional outcome in adult rats. In Aim 2, we investigate whether combination treatment with HUCBCs and simvastatin increases HUCBC migration into the ischemic brain. We hypothesize, that combination treatment with HUCBCs and simvastatin increases stromal derived factor 1 (SDF1) expression and enhances HUCBC homing/migration and survival in the ischemic brain. The increased HUCBC number in the ischemic brain increases functional outcome after stroke. Combination treatment with HUCBCs and simvastatin reduces infarct volume, and enhances angiogenesis and neurogenesis in the ischemic brain in rats. We will elucidate the effect of combination HUCBCs and simvastatin therapy with the intention of developing a viable restorative therapy to translate to the stroke population. Our study is a prototype and a proof of principle designed to augment the therapeutic response to the administration of exogenous cells for the treatment of stroke.

Public Health Relevance:
Stroke is the third leading cause of morbidity and long-term disability. Treatment of stroke has taken essentially two approaches, cellular and pharmacological therapy. We propose to combine cell and pharmacological treatment, to enhance recovery of neurological function post stroke. Our preliminary data show that the human umbilical cord blood cells (HUCBCs) treatment of stroke improves functional outcome. Combination of sub- therapeutic doses of simvastatin with HUCBCs increases exogenously administered cell migration into the ischemic brain and additively improves the therapeutic outcome after stroke. Thus, we propose that HUCBC cell-based therapy can be enhanced by making the tissue more receptive to the administered cells by creating a microenvironment within the ischemic cerebral tissue that facilitates cell-based induction of brain plasticity. A clinically relevant embolic middle cerebral artery occlusion (MCAo) rat model will be used in this study, which will provide new and important data regarding novel therapeutic targets for stroke recovery.

Thesaurus Terms:
21+ Years Old; Adjuvant; Adult; Apoplexy; Blood Cell Count; Blood Cell Number; Blood Cells; Blood, Cord; Body Tissues; Bone Marrow Stem Cell; Brain; Cell Locomotion; Cell Migration; Cell Movement; Cell Therapy; Cells; Cellular Migration; Cerebral Stroke; Cerebrovascular Apoplexy; Cerebrovascular Stroke; Cerebrovascular Accident; Cerebrum; Combined Modality Therapy; Common Rat Strains; Data; Dose; Encephalon; Encephalons; Figs; Figs - Dietary; Gvhd; Graft-Versus-Host Disease; Graft-Vs-Host Disease; Homologous Wasting Disease; Human; Human, Adult; Human, General; Infarction; Intention; Mammals, Rats; Man (Taxonomy); Man, Modern; Middle Cerebral Artery Occlusion; Modality; Modeling; Mono-S; Monos; Morbidity; Morbidity - Disease Rate; Motility; Motility, Cellular; Multimodal Therapy; Multimodal Treatment; Multimodality Treatment; Nervous System Physiology; Nervous System, Brain; Neural Growth; Neurologic; Neurologic Function; Neurological; Neurological Function; Neuronal Growth; Outcome; Peripheral Blood Cell; Pharmacological Treatment; Population; Rat; Rattus; Recovery; Regulation; Risk; Runt Disease; Simvastatin; Stroke; Synvinolin; Testing; Therapeutic; Therapeutic Effect; Therapy, Cell; Tissues; Translating; Translatings; Treatment Efficacy; Umbilical Cord Blood; Vascular Accident, Brain; Adult Human (21+); Adult Youth; Angiogenesis; Base; Brain Attack; Brain Tissue; Cell Motility; Cell-Based Therapy; Cerebral Vascular Accident; Clinical Relevance; Clinically Relevant; Combination Therapy; Combined Modality Treatment; Combined Treatment; Design; Designing; Disability; Fetal Cord Blood; Functional Outcomes; Improved; Infarct; Language Translation; Migration; Multimodality Therapy; Nervous System Function; Neurogenesis; New Therapeutic Target; Post Stroke; Poststroke; Prototype; Public Health Relevance; Response; Stroke; Stroke Recovery; Stroke Therapy; Therapeutic Efficacy; Therapeutically Effective; Young Adult

Phase II

Phase II year
---
Phase II Amount
---